223 related articles for article (PubMed ID: 10626286)
1. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
Fehmann HC; Wulbrand U; Arnold R
Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
Van Eijck CH
Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
[No Abstract] [Full Text] [Related]
3. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
4. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
5. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
6. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
8. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
Degen L; Beglinger C
Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
[TBL] [Abstract][Full Text] [Related]
9. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
10. Advances in the use of somatostatins in the management of endocrine tumors.
Chaudhry A; Kvols L
Curr Opin Oncol; 1996 Jan; 8(1):44-8. PubMed ID: 8868099
[TBL] [Abstract][Full Text] [Related]
11. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
13. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.
Eriksson B; Oberg K
Ann Oncol; 1999; 10 Suppl 2():S31-8. PubMed ID: 10399030
[TBL] [Abstract][Full Text] [Related]
14. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.
Arnold R; Wied M; Behr TH
Expert Opin Pharmacother; 2002 Jun; 3(6):643-56. PubMed ID: 12472080
[TBL] [Abstract][Full Text] [Related]
16. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
17. Future aspects of somatostatin-receptor-mediated therapy.
Oberg K
Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
20. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
